IONIS PHARMACEUTICALS INC — Director's Dealing 2015

Mar 20, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2015-03-18

Reporting Person: WENDER JOSEPH H (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-18	Common Stock	M	6100	$5.93	Acquired	36317	Direct
2015-03-18	Common Stock	S	6100	$70.948	Disposed	30217	Direct
2015-03-18	Common Stock	M	6400	$5.93	Acquired	36617	Direct
2015-03-18	Common Stock	S	6400	$71.8443	Disposed	30217	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-18	Director Stock Option (right to buy)	$5.93	M	12500	Disposed	2016-07-02	Common Stock (12500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30217	Indirect

Footnotes

F1: Acquired as a result of exercising a stock option.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.41 to $71.41, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.42 to $72.20, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.